Director Jean Jacques Bienaime acquired 1,000 shares of common stock in Keros Therapeutics (NASDAQ: KROS) on April 15, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were purchased at prices between $11.56 and $11.80, for a total outlay of $11,700.
The purchase was executed under a pre-arranged Rule 10b5-1 trading plan that Bienaime adopted on December 5, 2025. Following completion of the transaction, Bienaime now directly holds 8,450 shares of Keros Therapeutics common stock.
Keros shares were trading at $11.67 at the time the filing referenced, reflecting a 43% decline year-to-date. Despite the pullback in price, third-party analysis from InvestingPro cited in the filing indicates the company may be undervalued at current levels, with published analyst price targets spanning from $16 to $30.
On the company’s recent financials, Keros remains profitable on a trailing-twelve-month basis, reporting earnings per share of $2.30.
In separate corporate governance news, Keros Therapeutics announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026. Newton most recently served as Chief Financial Officer at Lyell Immunopharma from February 2021 until his retirement in September 2025.
Prior to his role at Lyell, Newton held senior roles in investment banking at Bank of America, Credit Suisse, and Morgan Stanley, where his work focused on the healthcare sector. He also holds board seats at Novavax, Inc. and Coherus Oncology, Inc.
The combination of insider purchasing activity and the addition of a finance-focused director provides shareholders and observers with concrete, documented developments related to ownership and leadership at Keros Therapeutics. The filing details and the board appointment were disclosed through the company’s regulatory submissions and corporate notices.
Below are the primary takeaways and considerations drawn from the filings and announcements:
- Insider purchase: 1,000 shares purchased on April 15, 2026, at $11.56 to $11.80 per share, totaling $11,700.
- Ownership update: Bienaime’s direct holdings increased to 8,450 shares after the trade.
- Valuation context: The stock traded at $11.67 and is down 43% year-to-date; InvestingPro analysis cited analyst targets from $16 to $30.
- Profitability: Keros reported trailing-twelve-month earnings per share of $2.30.
- Board change: Charles Newton joined the board effective March 9, 2026, bringing CFO experience at Lyell Immunopharma and prior investment banking experience focused on healthcare.
Each of these items is documented in the company’s regulatory filings and corporate announcements. The details above reflect the information disclosed by the company and in the Form 4 submission relating to the insider purchase.